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We previously reported that acetylcholinesterase plays a critical role in apoptosis and its expression is regulated by Ca2+ mobilization. In the
present study, we show that activated calpain, a cytosolic calcium-activated cysteine protease, and calcineurin, a calcium-dependent protein
phosphatase, regulate acetylcholinesterase expression during A23187-induced apoptosis. The calpain inhibitor, calpeptin, and the calcineurin
inhibitors, FK506 and cyclosporine A, inhibited acetylcholinesterase expression at both mRNA and protein levels and suppressed the activity of
the human acetylcholinesterase promoter. In contrast, overexpression of constitutively active calcineurin significantly activated the
acetylcholinesterase promoter. Furthermore, we identify a role for the transcription factor NFAT (nuclear factor of activated T cells), a
calcineurin target, in regulating the acetylcholinesterase promoter during ionophore-induced apoptosis. Overexpression of human NFATc3 and
NFATc4 greatly increased the acetylcholinesterase promoter activity in HeLa cells treated with A23187. Overexpression of constitutive nuclear
NFATc4 activated the acetylcholinesterase promoter independent of A23187, whereas overexpression of dominant-negative NFAT blocked
A23187-induced acetylcholinesterase promoter activation. These results indicate that calcineurin mediates acetylcholinesterase expression during
apoptosis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Acetylcholinesterase; Apoptosis; Calpain; Calcineurin; NFAT1. Introduction
Acetylcholinesterase (AChE) is a type B carboxylesterase
that rapidly hydrolyzes the neurotransmitter acetylcholine
(ACh) at cholinergic synapses and neuromuscular junctions
[1]. AChE is also involved in non-cholinergic processes such
as cell adhesion, neuritogenesis, hematopoiesis, and tumor-
igenesis [2,3]. The molecular mechanisms regulating ACHE
gene expression have been studied mostly in muscle [4–6],Abbreviations: AChE, Acetylcholinesterase, acetylcholine acetyl hydrolase;
CnA, calcineurin A; CnB, calcineurin B; CsA, cyclosporine A; DMSO,
dimethyl sulphoxide; NFAT, nuclear factor of activated T cells
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doi:10.1016/j.bbamcr.2007.01.008neurons and hematopoietic cells [2]. Although Stephenson and
his colleagues predicted AChE's involvement with apoptosis
based on its deletion from many leukemic lines in 1996 [7],
our studies have firstly shown that AChE expression can be
induced by various apoptosis stimuli in various cell types
including those cell types derived from non-muscle, non-
nervous and non-hematopoietic tissues, suggesting that AChE
is a novel regulator of apoptosis [8]. We also showed that
intracellular Ca2+ plays a critical role in regulating AChE
expression,through modulating AChE mRNA stability and
promoter activity, in HeLa cells during apoptosis triggered by
the calcium ionophore A23187 [9]. However, the exact
mechanisms by which Ca2+ regulates AChE expression during
apoptosis are not fully understood.
Intracellular Ca2+ is an important second messenger, and
modulates apoptosis by activating phospholipases, endonucleases,
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protease that is active during apoptosis is calpain [11–13].
Calpain is an intracellular cysteine protease that modulates
Ca2+-dependent apoptosis through a variety of mechanisms.
Activated calpain cleaves and activates caspase-12 and cyclin-
dependent kinase 5 (cdk5) to mediate calcium-triggered cell
death [13,14]. Calpain also cleaves cain/cabin 1, an endogen-
ous inhibitor of calcineurin, leading to its activation and
calcium-triggered cell death [11]. The best-characterized
calpains are two ubiquitously expressed isozymes, calpain I
(μ-calpain) and calpain II (m-calpain), which are each
composed of a large catalytic subunit (80 kDa) and a small
regulatory subunit (30 kDa). Activation of calpain I and II
requires micro- and millimolar concentrations of calcium,
respectively [15].
Calcineurin is a calmodulin (CaM)-binding protein and a
Ca2+-dependent serine/threonine phosphatase that is directly
regulated by Ca2+/CaM [16]. Calcineurin can also be cleaved
and activated by calpain [17–19]. Calcineurin consists of
one catalytic (CnA, 60 kDa) and one regulatory (CnB,
18 kDa) subunit [20]. A growing number of studies have
demonstrated the involvement of a calcineurin-dependent
apoptotic cascade following calcium increase during apop-
tosis [21–25]. During myogenesis, the activation of cal-
cineurin led to increased stability of AChE mRNA [26].
Moreover, we previously showed that Ca2+-dependent sig-
naling regulated AChE expression in HeLa cells during
A23187-induced apoptosis [9]. Together, these studies sug-
gest that the ACHE gene is a target of calcineurin. In this
study, we investigate the relationship between calpain, calci-
neurin and AChE expression during HeLa cell apoptosis
induced by A23187. We present evidence that calcineurin
activates AChE expression, likely through the activation of the
NFAT (nuclear factor of activated T cells) family of trans-
cription factors.
NFAT is a family of transcription factors present in cells and
tissues both inside and outside of the immune system [27] and
is composed of at least four members: NFAT1, NFAT2,
NFAT3, and NFAT4 (also called NFATp/NFATc2, NFATc/
NFATc1, NFATc4, and NFATx/NFATc3, respectively) [28].
Upon calcium mobilization, activated calcineurin dephosphor-
ylates NFATs, leading to their translocation to the nucleus
[29,30]. NFATs are rapidly phosphorylated and exported to the
cytoplasm upon termination of calcium signaling or by
calcineurin inhibition with CsA and FK506 [31]. NFATs bind
target gene promoters cooperatively with other nucleoproteins
to induce transcription, thus providing a direct link between
intracellular Ca2+ signaling and gene expression [28,31].
Recently, it was reported that in cultured rat muscle, NFATs
could modulate transcription of the mouse AChE promoter
[32]. In this study, we examine the regulation of the human
AChE promoter by overexpressing wild type and variant human
NFAT family proteins. Our data suggest that NFATs may be a
transcriptional regulator of the human ACHE gene, and suggest
for the first time that the calcineurin/NFAT pathway is involved
in the regulation of ACHE gene expression during Ca2+-
induced apoptosis.2. Materials and methods
2.1. Cell culture and treatments
HeLa cells were maintained in RPMI 1640 (GIBCO-BRL, Gaithersburg,
MD) with 10% heat-inactivated fetal bovine serum (GIBCO-BRL). Cells were
treated with DMSO (control) or A23187 (2 μM) (Calbiochem, Darmstadt,
Germany) for different times. In some experiments, HeLa cells were pre-incu-
bated with calpeptin, FK506, or CsA for 3 h, and then incubated with A23187
(2 μM).
2.2. Plasmid construction
A 2.2 kb fragment of the human AChE promoter [33] was subcloned into the
BglII andHindIII sites of the pGL3-Basic vector (Promega,Madison,WI), which
contains the firefly luciferase gene, to create pAChE-Luc [34]. A cDNA
encoding human calcineurin A (a kind gift from Dr. Chi-Wing Chow, Albert
Einstein College of Medicine, Bronx, New York) was amplified by PCR using
the following primers: F, 5′-AATGAATTCACATGTCCGAGCCCAAGGC-3′;
R, 5′-AATCTCGAGCTGAATATTGCTGCTATTACTGC-3′, and was then
subcloned between the BamHI and XholI sites of the pcDNA4a vector
(Invitrogen, Carlsbad, CA). A cDNA encoding human calcineurin B was
obtained from HeLa cells by the reverse transcription of total RNA, followed by
PCR using the following primers: F, 5′-AATGGATCCCGCCGAGCAAAAT-
GGGA-3′; R, 5′-AATCTCGAGCACATCTACCACCATCTTTTTGTGGA-3′,
and was cloned into the BamHI/XhoI sites of pcDNA4a. Constitutively active
calcineurin A (ΔCnA) was a generous gift of Dr. Michael Karin (University of
California, San Diego, La Jolla, CA). Full-length human NFATc3 and NFATc4
were provided by Dr. Vrushank Dave (Cincinnati Children's Hospital Medical
Center, Cincinnati, OH). A cDNA encoding human NFATc4 was cloned between
the BamHI and XbaI sites of pEGFP-C1 (Clontech, Mountain View, CA),
downstream of and in frame with the EGFP gene. Constitutive nuclear NFATc4
(cnNFATc4) and dominant-negative NFAT (dn NFAT) were supplied by Dr. Chi-
Wing Chow (Albert Einstein College of Medicine, Bronx, New York).
2.3. DNA fragmentation analysis
Cells were harvested, washed with PBS, pelleted, and resuspended in 40 μl
of 0.2 M Na2HPO4/4 mM citric acid. Cell preparations were then centrifuged
at 1500 g for 15 min, supernatants removed and 3 μl of 0.25% NP-40 and 3 μl
of RNase A (10 mg/ml) were added. After incubation at 37 °C for 60 min,
3 μl of proteinase K (10 mg/ml) was added and samples were incubated
30 min at 50° C. DNA was then visualized on 1.5% agarose gel by standard
procedures.
2.4. Semiquantitative RT-PCR and two step real-time quantitative
RT-PCR
Total RNAwas extracted fromHeLa cells using TRIzol Reagent (Invitrogen)
and was reverse transcribed using M-MLV Reverse Transcriptase (Promega,
Madison, WI). The resulting cDNAs were used as template to PCR-amplify
NFATc1 (386 bp fragment; F, 5′-CGCCCGCACGCCTTCTACCA-3′; R, 5′-
GACCATCTTCTTCCCGCCCACGAC-3′), NFATc2 (497 bp fragment; F,
5′-GCCGCCAGCCCGAGGTTCAC-3′; R, 5′-GGCGAGGCTGTTCAGGG-
CATCCAT-3′), NFATc3 (311 bp fragment; F, 5′-CCAGCCCGGGAGACTT-
CAATAGAT-3′; R, 5′-GCCCAGGAGCTTCACAACAGGAT-3′), NFATc4
(389 bp fragment; F, 5′-GGTTTCCCGGCCAGTCCAGGTCTA-3′; R, 5′-
AAGGGCGGGGAAGGAAGGAAACT-3′), and GAPDH (588 bp fragment;
5′-CCACCCATGGCAAATTCCATGGCA-3′; 5′-TCTAGACGGCAGGT-
CAGGTCC ACC-3′).
Real-time PCR was performed using the SYBR green I PCR kit (PE Biosys-
tems, Foster City, CA) and PE Biosystems GeneAmp 5700 sequence detection
system (PE Biosystems) as described previously [9]. AChE primers (F, 5′-
AGCCGAGGCTGTGGTCCTGCATTACA-3′; R, 5′-CGCATCAGTCGCT-
GGGCGAAGATTTT-3′) andGAPDHprimers (see above) were used. Reactions
were performed in triplicates, and AChE mRNA levels were calculated relative
to the GAPDH levels using the following formula: 2-(CtAChE-CtGAPDH)TimeX,
Fig. 1. A23187 induced apoptosis and increase in AChE expression in HeLa
cells. (A) DNA fragmentation analysis. (B) A23187-induced caspase-3
activation in HeLa cells. Western blot analysis of extract of HeLa cells treated
with DMSO (control) or A23187 (2 μM) for indicated time. (C) AChE protein
level was analyzed by Western blot after HeLa cells were treated with DMSO
(control) or A23187 (2 μM) for indicated time.
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“TimeX” is the corresponding time point.
2.5. Western blotting
Immunoblotting was carried out as described previously [8]. The following
primary antibodies were used: monoclonal anti-AChE antibody (BD Bios-
ciences, San Jose, CA); monoclonal anti-actin antibody (Sigma, St. Louis, MO),
polyclonal rabbit anti-calpain I large subunit (μ-type) antibody (Cell Signaling
Technology, Beverly, MA) and polyclonal rabbit anti-cleaved caspase-3 (Cell
Signaling Technology). The following secondary antibodies were used: HRP-
conjugated goat anti-mouse and goat anti-rabbit antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA). Western blots were visualized using a
chemiluminescence detection kit (ECL, Santa Cruz Biotechnology).
2.6. Transient transfections and luciferase assays
HeLa cells were transfected with the pAChE-Luc firefly luciferase reporter
construct or the control renilla luciferase reporter plasmid pRL-SV40 (Promega,
Madison, WI) using LipofectAMINE regent (Invitrogen). Each well of HeLa
cells was co-transfected with pAChE-Luc (0.3 μg) and pRL-SV40 (0.03 μg).
For co-transfection of the calcineurin and NFAT expression vectors, total DNA
was normalized with corresponding empty vectors. Twenty-four hours after
transfection, apoptosis was induced using 2 μM A23187. Luciferase activity
assays were performed according the Dual-Luciferase Reporter Assay System
(Promega), and activities were measured using a luminometerBGP (MGM).
AChE promoter activity was analyzed by firefly luciferase activity normalized to
renilla luciferase activity in each well.
2.7. Calcineurin phosphatase assay
After treatment, cells were collected, pelleted by centrifugation and lysed in a
buffer (50 mMTris–HCl pH 7.5, 10 mMEDTA, 100 mMNaCl, and 0.1% Triton
X-100, 1 mM PMSF, 1 μg/ml Aprotinin, and 1.0 μM Pepstain A). Phosphate-
reduced samples were prepared and calcineurin (also known as protein
phosphatase 2B) activity was detected using the serine/threonine Phosphatase
Assay System according to the manufacturer's instructions (Technical Bulletin
no.218; Promega, Madison, WI). Upon addition of calmodulin, the amount of
phosphate released from the phosphopeptide substrate was measured using
molybdate dye solution.
2.8. Microscopic techniques
For NFAT localization studies, HeLa cells were transfected with pEGFP-
NFATc4. Apoptosis was induced using 2 μM A23187 24 h later. After 90 min,
treated and untreated cells were washed with PBS, plated on coverslips. The
fluorescence signals were observed under a TCS NT laser confocal microscope
(Leica Microsystems, Bensheim, Germany).
2.9. Statistical analyses
Each experiment was repeated at least three times and results were expressed
as means±S.E.M. **p<0.005 and *p<0.05 were calculated using Student's
two-tailed t test.3. Results
3.1. Induction of AChE expression and activation of calpain
and calcineurin during apoptosis triggered by A23187
A23187 is a Ca2+ ionophore that equilibrates Ca2+ gradients
across membranes and can cause a rapid rise in intracellular Ca2+
levels. A23187 induced DNA fragmentation, a hallmark of
apoptosis, in HeLa cells and this was particularly evident after48 h of A23187 treatment (Fig. 1A). Cleavage of caspase-3 is
another hallmark of apoptosis. A23187 treatment led to in-
creased caspase-3 cleavage over a 72 h period (Fig. 1B). AChE
protein expression following A23187 treatment was also evident
as detected by Western blot analysis (Fig. 1C). Interestingly,
AChE protein levels were detectable as early as 12 h after
A23187 treatment, in spite of a lack of significant morphological
features of apoptosis.
Calpain is frequently activated during calcium-induced
apoptosis [12,13,35], and A23187 treatment can lead to calpain
activation [11], as evidenced by autoproteolytic cleavage of the
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HeLa cells to A23187, the 75 kDa fragment of calpain I
increased to peak levels by 24 h and then decreased thereafter
(Fig. 2A). Interestingly, the 80 kDa fragment of calpain I did not
decrease until 48 h of ionophore treatment, suggesting that
A23187 may also increase calpain I expression. Notably, when
HeLa cells were preincubated for 3 h with calpeptin, a calpain
inhibitor, then treated with A23187, calpain I autoproteolysis
was inhibited in a concentration dependent manner (Fig. 2B),
confirming A23187 increases the activity of calpain in HeLa
cells.
It is known that calcineurin could be activated in a calpain-
dependent manner and mediated calcium-triggered cell death
[11]. We then measured calcineurin activity during A23187-
induced HeLa cell apoptosis. Fig. 3A shows that A23187
produced a time-dependent increase in calcineurin activity in
HeLa cells. The increased activity was inhibited by FK506 and
cyclosporin (CsA), two inhibitors of calcineurin, in a dose-Fig. 2. Calpain was activated during HeLa cell apoptosis induced by A23187.
(A) A23187 increased the 75 kDa fragment of calpain I in HeLa cells. (B) The
calpain inhibitor, calpeptin, inhibited calpain expression. HeLa cells were
treated with DMSO or A23187 (2 μM) for 24 h in the absence or presence of
calpeptin pretreatment for 3 h. Calpain I protein levels were analyzed byWestern
blot.
Fig. 3. Calcineurin was activated during HeLa cell apoptosis induced by
A23187. (A) HeLa cells were treated with DMSO (control) or A23187 (2 μM).
Cellular calcineurin activity was determined. (B) Cellular calcineurin activity
was measured after HeLa cells were treated with DMSO or A23187 (2 μM) for
24 h in the absence or presence of inhibitors pretreatment for 3 h. *p<0.05
values are significantly different from cells incubated with A23187.dependent manner (Fig. 3B). When HeLa cells were preincu-
bated with calpeptin, calcineurin activation was also suppressed
in A23187 treated cells, indicating that calcineurin activation
requires calpain (Fig. 3B).
3.2. Induction of AChE expression during A23187-induced
apoptosis is regulated by calpain and calcineurin
To determine whether the induction of AChE expression
and activation of calpain and calcineurin are causally related,
we investigated the effects of calpain and calcineurin
inhibitors on A23187-induced AChE expression. HeLa cells
were pretreated with the calpain inhibitor calpeptin or cal-
cineurin inhibitors FK506 and CsA for 3 h, followed by
A23187 treatment for 24 h. Whole cell extracts were then
prepared for analyzing AChE mRNA and protein levels. We
have previously reported that the 482 bp tailed AChE-T
fragment, but not the AChE-E and AChE-R fragments, was
induced during HeLa cell apoptosis induced by A23187
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study, AChE-T mRNA fragment levels were measured by
real-time RT-PCR, and the housekeeping gene GAPDH was
used as an internal control. Calpeptin, FK506, or CsA
treatment led to a decrease in AChE mRNA levels in dose-
dependent manners (Fig. 4A, C, and E). Western blot analysis
revealed that AChE protein levels were also decreased by
these inhibitors in dose-dependent manners, whereas control
actin levels were unchanged (Fig. 4B, D, and F). These results
suggest that A23187-induced AChE expression requires both
calpain and calcineurin.Fig. 4. Increases in AChE mRNA and protein expression during A23187-induced ap
were analyzed by real-time quantitative RT-PCR and AChE protein levels were analyz
for 24 h in the absence or presence of inhibitors pretreatment for 3 h. **p<0.005 an3.3. Calcineurin is required for activation of the AChE
promoter during A23187-induced apoptosis
To determine whether calpain and calcineurin are required
for A23187-induced AChE promoter activity, we transiently co-
transfected HeLa cells with a reporter construct containing a
2.2-kb fragment of the human AChE promoter fused to the
firefly luciferase reporter gene (pAChE-Luc) and an internal
control renilla luciferase reporter plasmid (pRL-SV40). Cells
were then treated with and without A23187 (2 μM) in the
presence or absence of calpeptin, FK506, or CsA. As shown inoptosis were blocked by calpain and calcineurin inhibitors. AChE mRNA levels
ed by Western blot after HeLa cells were treated with DMSO or A23187 (2 μM)
d *p<0.05 values are significantly different from cells incubated with A23187.
Fig. 5. The human AChE promoter activities were mediated by calcineurin. (A)
Each well of HeLa cells was co-transfected with pAChE-Luc and pRL-SV40.
(B) Each well of HeLa cells was co-transfected with pAChE-Luc, pRL-SV40,
along with expression vectors for CnA (0.1 μg), or ΔCnA (0.1 μg). Each well
was also co-transfected with CnB (0.1 μg). Empty vectors appear as MOCK.
AChE promoter activity was analyzed after transfected HeLa cells were treated
with DMSO or A23187 (2 μM) for 24 h in the absence or presence of inhibitors
pretreatment for 3 h (A, B). *p<0.05 values are significantly different from cells
incubated with A23187. (C) Each well of cells was co-transfected with pAChE-
Luc, pRL-SV40, along with different amounts of ΔCnA and relative empty
vectors. Each well was also co-transfected with CnB (0.5 μg). After 24 h, AChE
promoter activity was analyzed in each well.
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promoter activation in dose-dependent manners. These results
suggest that calpain and calcineurin play a role in modulating
AChE promoter activity.
To test whether the ACHE gene responds to a calcineurin-
stimulated signaling pathway, we co-transfected pAChE-Luc
and pRL-SV40, with expression vectors encoding the calci-
neurin catalytic A (CnA), and regulatory (CnB) subunits. Co-
transfection of full-length CnA and CnB did not obviously
activate the AChE promoter in HeLa cells without treatment of
A23187. However, in the presence of A23187, overexpression
of CnA and CnB caused a significant increase in the AChE
promoter activity (Fig. 5B). To test whether calcineurin is
directly involved in AChE promoter activation, we co-
transfected cells with a C-terminal deleted form of calcineurin
(ΔCnA) which is constitutively active even in the absence of
elevated calcium [37]. Compared with cells expressing full-
length CnA and CnB, those cells co-transfected withΔCnA and
CnB exhibited high AChE promoter activity in the absence of
A23187 (Fig. 5B). In the presence of A23187, AChE promoter
activity was further upregulated, indicating activation of
endogenous calcineurin. FK506 and CsA can also block the
effects of ΔCnA on AChE expression (Fig. 5B). Fig. 5C shows
that ΔCnA activated the AChE promoter in a dose-dependent
manner. These data indicated that calcineurin is both necessary
and sufficient to increase AChE promoter activity in HeLa cells
in a calcium-dependent manner.
3.4. The NFAT family of transcription factors is involved in the
activation of the AChE promoter in A23187-treated cells
One target of calcineurin is NFAT (nuclear factor of
activated T cells). NFAT transcription factors translocate from
the cytoplasm to the nucleus following dephosphorylation by
calcineurin in some systems [29,30]. Thus NFAT factors are
good candidates for mediating calcineurin-dependent regula-
tion of the AChE promoter. To investigate this possibility,
we first examined the expression of NFAT genes in HeLa
cells by RT-PCR. Using primers that specifically recognize
NFATc1, NFATc2, NFATc3, and NFATc4, we were able to
PCR-amplify products of expected sizes (Fig. 6), suggesting
that these four NFAT genes are expressed in HeLa cells.
Based on band intensity, NFATc3 is present at high levels
(Fig. 6, lane 4), NFATc1 and NFATc4 at intermediate levels,
(Fig. 6 lanes 2 and 5), and NFATc2 is present at low levels
(Fig. 6, lane 3).
We next examined whether NFAT factors translocated to
the nucleus in response to A23187 treatment. We transfected
an expression construct encoding an EGFP–NFATc4 fusion
protein into HeLa cells, and treated with and without A23187.
Ninety minutes after treatment, treated and untreated cells
were examined by fluorescence microscopy to determine the
cellular localization of green fluorescence. In control cultures,
green fluorescence was mainly distributed in cytoplasm and
was excluded from nuclei (Fig. 7A). In contrast, green
fluorescence was detectable in nuclei of A23187-treated cells
(Fig. 7B).
Fig. 7. NFATc4 translocated to the nucleus in HeLa cells induced by A23187.
HeLa cells were transfected with an expression construct (pEGFP-NFATc4)
encoding an EGFP-NFATc4 fusion protein. Twenty-four hours later, transfected
cells were left untreated (A) or treated with A23187 (2 μM) (B). After 90 min,
treated and untreated cells were washed with PBS and viewed by fluorescence
microscopy to determine the cellular localization of green fluorescence.
Fig. 6. Expression of NFAT mRNA in HeLa cells. Semi-quantitative RT-PCR
was performed on total RNA isolated from HeLa cells. Unique sets of primer
pairs were for each gene. GADPH mRNA was amplified as internal control.
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activation of the AChE promoter, we co-transfected the pAChE-
Luc and pRL-SV40 reporter construct into HeLa cells along
with expression constructs encoding wild type human NFATc3
or NFATc4 gene. In the absence of A23187 treatment, the
NFATc3 and NFATc4 did not significantly activate the AChE
reporter construct, whereas increased promoter activity was
observed after treatment with A23187 in the presence of
NFATc3 or NFATc4 than without these factors (Fig. 8A and C).
Activation of the AChE reporter construct by overexpression of
constitutively active calcineurin (ΔCnA) was further increased
by co-expression of NFAT factors (Fig. 8A and C). The increase
in AChE promoter activity in cells treated with A23187 and
overexpressing NFATc3 and NFATc4 was blocked by co-
transfection of a dominant-negative NFAT (dnNFAT) expres-
sion vector [38] (Fig. 8B and D). The dnNFAT (NFAT3 amino
acids 1–130) has been shown to specifically inhibit NFAT-
mediated gene expression by preventing nuclear translocation
[39]. We also co-transfected of pAChE-Luc and pRL-SV40
along with an expression vector encoding a constitutive nuclear
NFATc4 (cnNFATc4), in which conserved serine residues have
been replaced with alanines to promote nuclear localization and
increased transcriptional activity [38,40]. Remarkably, co-
transfection cnNFATc4 with the AChE reporter construct
activated the AChE promoter in a dose-dependent manner
independently of A23187 treatment (Fig. 8E). These results
suggest that NFAT family members could be potent transcrip-
tional regulators of the ACHE gene. In addition, Fig. 8F shows
that A23187-dependent AChE promoter activity was blocked
by co-expression of the dnNFAT, indicating inhibition of the
endogenous NFAT by dnNFAT. Together these results suggest
that NFAT factors are involved in the A23187-induced increase
of the AChE promoter activity in HeLa cells.
4. Discussion
Previous studies suggested that AChE could be a novel
regulator of apoptosis [8,41]. Elucidating the regulatory
mechanisms of AChE expression during apoptosis may leadto better therapies that involve apoptosis modulation, such as
cancers Alzheimer's and Parkinson's disease [42]. Ca2+ is one
of the most important signaling agents in mammalian cells,
acting as a messenger to regulate growth, differentiation, and
apoptosis. Coordination of all these signaling functions requires
precise regulation of intracellular Ca2+ levels. We have shown
that intracellular Ca2+ plays a critical role in regulating AChE
expression during apoptosis [9]. Calpain and calcineurin are
two important mediators of the effects of increased Ca2+ levels.
In this study, we choose HeLa cells, a cell line that does not
express AChE strongly in normal states as previously reported
[9]. We demonstrated that AChE up-regulation during HeLa
apoptosis induced by A23187 was mediated by calpain/
calcineurin pathway.
Calpain and calcineurin may regulate apoptosis through a
variety of mechanisms. Calpain can cleave pro-apoptotic
proteins such as caspase-12, Bax, and Bid, leading to an
increase in their activity [13,43,44]. Our results show that one of
calpain inhibitor, calpeptin, blocked A23187-induced AChE
expression at both mRNA and protein levels, suggesting that
calpain may mediate AChE up-regulation indirectly without
cleaving it. We also found that calpeptin suppressed the increase
in calcineurin activity in A23187-treated HeLa cells, indicating
that calcineurin activation was calpain-dependent. It has been
reported that calpain, which is activated by increased cytoplas-
mic Ca2+, can cleave the endogenous calcineurin inhibitor cain/
cabin1 leading to activation of calcineurin [11], suggesting a
mechanism for how calcineurin is activated by a rise in the
cytoplasmic Ca2+ concentration. Calcineurin seems to have a
dual function and could exert its effects on apoptosis either by
the activation of specific transcriptional pathways or by direct
de-phosphorylation of proteins including BAD and caspase-9
involved in the apoptotic pathway [24,45,46]. Using the
calcineurin inhibitors FK506 and CsA, we have found evidence
that calcineurin is required for A23187-induced AChE expres-
sion. Overexpression of calcineurin greatly increased the
activity of the human AChE promoter in A23187-treated
cells, whereas calcineurin inhibitors lowered the increase in
Fig. 8. NFAT proteins were involved in the A23187-induced activation of the human AChE promoter. (A, C) Each well of HeLa cells was co-transfected with pAChE-
Luc, pRL-SV40, along with expression vectors for human NFATc3 (0.1 μg) (A)/ human NFATc4 (0.1 μg) (C), or constitutively active ΔCnA (0.1 μg), or NFATc3
(0.1 μg) (A)/ human NFATc4 (0.1 μg) (C) plusΔCnA (0.1 μg). Each well was also co-transfected with CnB (0.1 μg) and relative empty vectors. Empty vectors appear
as MOCK. (B, D) Each well of cells was co-transfected with pAChE-Luc, pRL-SV40, along with expression vectors for human NFATc3 (0.1 μg) (B)/ human NFATc4
(0.1 μg) (D), or NFATc3 (0.1 μg) (B)/ human NFATc4 (0.1 μg) (D) plus dnNFAT (0.1 μg). Each well was also co-transfected with relative empty vectors. Empty
vectors appear as MOCK. AChE promoter activity was analyzed in each well after transfected cells were incubated with DMSO or A23187 (2 μM) for 24 h (A–D).
(E) Constitutive nuclear NFATc4 (cnNFATc4) activated the human AChE promoter in HeLa cells. Each well of HeLa cells was co-transfected with pAChE-Luc,
pRL-SV40, along with different amounts of constitutive nuclear NFATc4 (cnNFATc4) and empty vectors. After 24 h, AChE promoter activity was analyzed in each
well. (F) Dominant-negative NFAT (dnNFAT) blocked A23187-dependent AChE promoter activity. Each well of HeLa cells was co-transfected with pAChE-Luc,
pRL-SV40, along with expression vectors for cnNFATc4 (0.1 μg) or dnNFAT (0.1 μg). Empty vectors appear as MOCK. AChE promoter activity was analyzed in
each well after transfected cells were incubated with DMSO or A23187 (2 μM) for 24 h.
600 H. Zhu et al. / Biochimica et Biophysica Acta 1773 (2007) 593–602A23187-induced AChE promoter activity. In addition, over-
expression of constitutively active calcineurin activated the
human AChE promoter independent of A23187. These datasuggest that calcineurin mediates A23187-induced AChE
expression at least through activation of specific transcriptional
pathways. Importantly, it has been reported previously that
601H. Zhu et al. / Biochimica et Biophysica Acta 1773 (2007) 593–602blocking AChE expression with antisense of AChE inhibited
apoptosis [8]. Furthermore, siRNA-mediated knockdown of
AChE abolished decrease of cell viability [41], suggesting that
AChE is an important regulator of apoptosis. We show now that
calcineurin plays a critical role in apoptosis by mediating the
expression of the ACHE gene.
Calcineurin controls gene expression via de-phosphoryla-
tion of transcription factors, such as NFAT, MEF2, NF-κB,
CREB, and Elk-1, affecting their nuclear localization and
influences the regulation of proteins involved in the survival
and apoptotic pathways [45]. For example, the InsP3 receptor
is a downstream target for NFAT mediated by Ca2+-dependent
calcineurin/NFAT pathway [47]. Our results indicate that
calcineurin signaling is both necessary and sufficient to
regulate human AChE promoter activity during A23187-
induced cell apoptosis. This activity may be mediated directly
by the NFAT family of transcription factors. Overexpression of
NFATc3 and NFATc4 greatly increased the human AChE
promoter activity in A23187-treated cells whereas dominant-
negative NFAT (dnNFAT) blocked the A23187-induced AChE
promoter activity. Overexpression of constitutive nuclear
NFATc4 directly activated human AChE promoter. These
results suggest that NFAT proteins were also necessary and
sufficient for AChE promoter activity during ionophore-
induced apoptosis. NFATs are expressed in many cell types
and contribute to diverse cellular functions [28]. The
calcineurin/NFAT signaling pathway has recently been impli-
cated in development and function of the nervous system, the
cardiovascular system, the musculoskeletal development, and
in cardiac growth and function [31,48]. It is also reported that
there is an induction of a NFAT-dependent luciferase reporter
by ionomycin and PMA in HeLa cells, indicating NFAT is
activated by calcium in a calcineurin-dependent fashion in
HeLa cells [49]. The calcineurin/NFAT signaling pathway is
also activated by the calcium ionophore A23187 [11,28,50].
Our studies are the first to suggest that calcineurin/NFAT
pathway regulates human ACHE gene expression during Ca2+-
induced cell apoptosis.
Regulation of calcium, apoptosis, and calcineurin signaling
has important consequences for disease, particularly Alzhei-
mer's disease (AD). AD is a neurodegenerative disorder
characterized by extensive neuronal loss which may be due to
apoptosis [51,52]. Dysregulation of intracellular calcium
signaling has been implicated in the pathogenesis of AD
[53], and increased levels of calcineurin A mRNA have been
detected in Alzheimer's diseased brain by microarray [54].
Elevated cleavage and activation of calpain has also been
associated with early stage AD [55–57], which in turn leads
to calcineurin activation. Interestingly, AChE activity has also
been reported to be increased in plaques and tangles early in
the onset of AD [58,59]. Our results suggest that the
activation of calcineurin in AD may lead to AChE expression
and neuronal death, suggesting a new mechanism for the
pathogenesis of AD. Further investigation into the mechan-
isms of AChE regulation and function during apoptosis could
contribute to the development of fruitful therapeutic approa-
ches to treatment of AD.Acknowledgements
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